The Problem of Homogeneity Among RCT Participants Despite recommendations for the inclusion of diverse racial and ethnic groups by federal grant and regulatory agencies, cardiovascular trial populations remain predominantly male, White, and from North America and Europe.1 BIPOC across the world bear the greatest burden of cardiovascular disease, but comprise a small proportion of RCT participants.1 In a systematic review of heart failure RCTs published between 2000 and 2020 in high-impact journals, <38% of RCTs reported the racial and ethnic...